<DOC>
	<DOCNO>NCT01782235</DOCNO>
	<brief_summary>Primary Sjögren 's syndrome ( pSS ) systemic autoimmune disease characterize lymphocytic infiltration lead destruction acinar ductal cell loss glandular parenchyma . The main symptom pSS dry eye dry mouth , diffuse pain , fatigue . One third patient develop systemic feature , severe lymphoma . Serum IL-6 increase serum , saliva , tear patient pSS . IL-6 play pivotal role B-cell activation , hallmark pathogenesis pSS , T-cell differentiation . Tocilizumab , recombinant humanise monoclonal antibody act IL-6R antagonist . The aim randomise double blind placebo control trial i evaluate efficacy tocilizumab treatment pSS .</brief_summary>
	<brief_title>Efficacy Tocilizumab Primary Sjögren 's Syndrome .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>Inclusion Criteria : Patient primary Sjögren 's syndrome accord European American consensus group criterion . Presence anti SSA ( Ro ) antiSSA antiSSB ( La ) antibodies ESSDAI score ≥ 5 . In woman childbearing age , effective contraception treatment 3 month follow treatment discontinuation . Patient previous history therapy tocilizumab . Prednisone treatment introduce two week inclusion change drug dose within two week inclusion . A prednisone dose ≥ 15 mg per day . Nonsteroidal antiinflammatory drug , pilocarpine hydrochloride , cyclosporine , cimeviline introduce within two week inclusion . Therapy methotrexate , Hydroxychloroquine , chloroquine , quinacrine , leflunomide , psychoactive drug introduce within 8 week inclusion dose change within 8 week inclusion . Treatment azathioprine mycophenolate mofetil within 8 week inclusion . Live live attenuate vaccine give within 4 week inclusion . Any biologic treatment within 6 month inclusion . Treatment cyclophosphamide , intravenous immunoglobulin therapy plasmapharese therapy last 6 month inclusion . Systemic autoimmune disease . Patient previous history diverticular perforation , complication diverticulitis , peritonite inflammatory bowel disease ( Crohn 's disease Colitis ulcerative ) . Patient history severe infection within 4 week inclusion . Patient history infection within 2 week inclusion . Patient chronic infection infection return ( e.g . tuberculose , VHB , VHC… ) . Positive serology test HIV , HBV , HCV . Severe uncontrolled dyslipidemia . Hepatocellular insufficiency . Unstable cardiovascular disease . Severe chronic kidney disease , severe chronic lung disease , severe chronic endocrine disorder , severe chronic neurological disease ( related SJP ) . Patient history solid organ transplantation haematopoietic stem cell transplantation . Patient history lymphoma , neoplasia diagnose 5 year inclusion except squamous basal cell cancer carcinoma situ uterine cervix . Severe complication SJp inclusion : vasculitis renal neurologic , digestive cardiac involvement , interstitial lung disease , symptomatic cryoglobulinemia severe neurologic involvement , renal function impairment , severe myositis , corticotherapy ≥ 1 mg/kg last 30 day inclusion . Neutropenia &lt; 1000*10^6 . Thrombocytopenia &lt; 50 000/µl ALT AST &gt; 3 x ULN alcohol drug addiction : withdrawal least one year inclusion A major surgical procedure 8 week inclusion schedule major surgery Pregnant woman , breast feed woman Adults supervision guardianship Patient take part another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>